Moneycontrolresearch

Rising AI demand, stricter data-localisation norms augur well for domestic cloud infrastructure providers

Krsnaa Diagnostics: Steering towards new growth horizons

The company is targeting 40-50% of revenue mix from its retail business

IndusInd Bank: Can this be a stock for the long term?

The new management is building a robust business with a diversified de-risked asset book and a granular liability franchise

Does this auto ancillary stock merit a place in your portfolio?

CAL’s aluminium business remains a key growth driver aided by acquisitions of DR Axion and Sunbeam

Max Healthcare Q2 FY26: Improved valuation comfort

The company plans to double its capacity in 4-5 years

Endurance Technology Q2 FY26: Multiple catalysts at work

The company is leveraging structural industry shifts, regulatory changes, and strategic partnerships to drive growth

Suraksha Diagnostics Q2 FY26: Offering a long-term investment case

It is a scalable play on India’s evolving healthcare demand

Global Health Q2 FY26: Healthy performance, strong outlook

The upcoming greenfield projects will help Medanta to establish a presence in western and eastern India

SJS Enterprises: The earnings momentum remains strong in Q2

SJS expects to grow at 2.5x the industry volume in FY26

Is recovery in sight for ZF Commercial Vehicle?

The management remains optimistic about outperforming industry growth, supported by a robust pipeline of new products, stronger aftermarket business, and favourable regulatory developments

Is the fertiliser sector becoming investment worthy?

The latest GST reforms address the key issue of the inverted duty structure

Krsnaa Diagnostics: Chasing new avenues for growth

Optimistic guidance for FY26; the B2C segment should act as a key growth lever

Rainbow Children’s Medicare: A high-potential, high-execution play

The Indian healthcare market is experiencing robust growth and the hospital chain is uniquely placed in the paediatric segment

Global Health: In the pink of health, but growth will come at a price

Demand for high-end healthcare facilities remains strong; however, the company’s valuation appears demanding

Apollo Hospital: Growth momentum continues in Q1 FY26

Robust expansion plans in place, with a target of about 4,000 beds in the next 3-4 years

Bluestone Jewellery and Lifestyle IPO: Will it shine on the bourses?

The company is not profitable at the moment and may continue to make losses in the near term

Bosch Q1 FY26: Is the auto ancillary stock racing too fast?

Bosch is planning to strengthen its competitive position in the mobility sector and industrial technology. It is actively adding new components, particularly those catering to EVs and advanced electronics.

Gabriel India: Primed for growth but priced to perfection

Forays into new segments like sunroof, inorganic and organic strategies show the company’s confidence in the future.

SJS Enterprises Q1 FY26: On track to meet growth targets

SJS expects to grow at 2x the industry volume in FY26 and maintain a ~26 percent margin level.

Brigade Hotel Ventures: Does the IPO offer a good investment opportunity?

The hotelier’s return ratios are solid and the stock valuation is attractive while part of the IPO money will support growth plans

Optimism low on this healthcare stock

Medanta has strong capabilities to leverage its brand image. However, near-term growth looks limited

How is the health of this healthcare stock?

Timely execution and ramp-up of new projects are crucial for faster growth

This hospital chain is aiming for high growth, but is it already priced in?

Max is on an aggressive expansion path with healthy medium-term growth visibility

Apollo Hospitals: Annual report card ticks all the right boxes

Robust expansion plans in place with the target to add a total of about 4000 beds in the next 3-4 years

Rallis India: Stars align in Q2, what does its pitch report say?

The company is focusing on optimising portfolio and streamlining capacities